Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCLINASDAQ:LIFENASDAQ:TCRRNASDAQ:UPTD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.53+3.9%$0.46$0.13▼$3.37$36.36M0.281.02 million shs1.01 million shsLIFEaTyr Pharma$1.60-1.2%$1.85$1.08▼$2.70$108.71M1.25514,669 shs159,073 shsTCRRTCR2 Therapeutics$1.48-5.7%$1.65$0.82▼$3.88$58.11M1.95494,777 shs3.91 million shsUPTDTradeUP Acquisition$1.03-8.0%$1.51$6.88▼$33.00$2.23M0.12270,115 shs64,318 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics-4.90%-10.88%+44.59%+83.29%-80.30%LIFEaTyr Pharma+1.89%-7.95%-19.00%+8.00%-13.37%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%-14.94%UPTDTradeUP Acquisition+3.23%-5.08%+1.82%+9.80%-89.52%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics1.2408 of 5 stars0.03.00.04.73.70.00.6LIFEaTyr Pharma1.9582 of 5 stars3.43.00.00.03.21.70.0TCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics2.00HoldN/AN/ALIFEaTyr Pharma2.75Moderate Buy$23.671,379.17% UpsideTCRRTCR2 TherapeuticsN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/ACurrent Analyst RatingsLatest UPTD, LIFE, BCLI, and TCRR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/ALIFEaTyr Pharma$353K307.95N/AN/A$1.54 per share1.04TCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/AUPTDTradeUP AcquisitionN/AN/AN/AN/A($1.59) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)LIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)TCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/AUPTDTradeUP Acquisition-$1MN/A0.00∞N/AN/AN/A-3.38%N/ALatest UPTD, LIFE, BCLI, and TCRR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023LIFEaTyr Pharma-$0.23-$0.25-$0.02-$0.25N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.240.24LIFEaTyr Pharma0.026.276.27TCRRTCR2 TherapeuticsN/A2.962.96UPTDTradeUP AcquisitionN/A0.090.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%LIFEaTyr Pharma61.72%TCRRTCR2 Therapeutics64.76%UPTDTradeUP Acquisition34.95%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics5.45%LIFEaTyr Pharma3.70%TCRRTCR2 Therapeutics25.01%UPTDTradeUP Acquisition55.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics2968.34 million64.62 millionOptionableLIFEaTyr Pharma5667.94 million65.43 millionOptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableUPTDTradeUP Acquisition2,0212.17 million973,000Not OptionableUPTD, LIFE, BCLI, and TCRR HeadlinesSourceHeadlineEstrella Immunopharma stock plunges in market debut after SPAC mergermsn.com - October 2 at 11:52 PMSPAC TradeUp, Estrella Biopharma complete merger; shares to debut Oct. 2msn.com - September 29 at 3:26 PMTradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combinationfinance.yahoo.com - September 29 at 3:26 PMTradeUP (UPTD) Stock is Up: What's Going On?benzinga.com - September 21 at 8:30 PMTradeUp (NASDAQ: UPTD) up 67% - Hey, maybe a deal really will be done heredhakatribune.com - September 15 at 4:38 PMWhy TradeUP Acquisition (UPTD) Stock Is Rocketing Higherbenzinga.com - September 1 at 3:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideBlackstone’s $10 Billion Bet on Property Prices Going UpApril 11, 2024 7:30 AMView Blackstone’s $10 Billion Bet on Property Prices Going UpAll Headlines Company DescriptionsBrainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.TCR2 TherapeuticsNASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.TradeUP AcquisitionNASDAQ:UPTDTradeUP Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.